Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. develops the Nautilus Voyager proteomics platform, an integrated system that combines instruments, consumables, and software analysis for large-scale protein analysis. The company is based in the United States and operates as a development-stage life sciences tools business with its platform still under development.

13.33

13.33

— Nautilus Biotechnology, Inc.
%
Instrumentation40% The Nautilus Voyager instrument automates assay chemistry and optical imaging for proteomics workflows.
Consumables25% Reagents and run-based consumables used with the Nautilus platform.
Software and analytics20% Software tools used to process and analyze proteomics data generated by the platform.
Service-based access15% Controlled access to the platform through service laboratory operations and early customer workflows.

Nautilus targets research customers that already work in proteomics or adjacent multi-omics workflows and need...

  • Pharmaceutical companiesprimary

    Buy platform access and future instruments to support discovery, biomarker, and translational proteomics work.

  • Biotechnology companiesprimary

    Use the platform for research programs that need multiplexed protein measurement and workflow automation.

  • Academic research institutionsprimary

    Purchase access for basic and applied proteomics research funded by grants and institutional budgets.

  • Multi-omics research centerssecondary

    Adopt the platform to combine proteomics with other omics datasets in specialized research programs.

  • Clinical development and CRO customersemerging

    Potential future users for translational studies and outsourced research services as the platform matures.

Nautilus is headquartered in the United States and currently assembles systems in San Carlos, California, using...

  • •United States is the initial commercialization market
  • •San Carlos, California is an in-house assembly location
  • •External manufacturers supply components for the system
  • •Europe and the UK are planned expansion markets
  • •Asia-Pacific is a potential later-stage commercial region

Nautilus is pursuing a phased commercialization model that starts with service-based access and limited system exposure...

01
Phased commercial launchshort-term

A controlled rollout helps refine workflows and reduce early adoption risk.

02
Build commercial infrastructureshort-term

Sales, marketing, service, and distribution capabilities are needed for market entry.

03
Advance product developmentmedium-term

The platform must complete technical development and testing before broad commercialization.

04
Expand intellectual propertymedium-term

Patents and know-how help protect the platform in a competitive proteomics market.

Nautilus is a development-stage company with no commercial product revenue, so its business depends on successfully...

critical

Development-stage business risk

The company has not commercialized products and may never reach profitable scale.

Scope
Entire business
Materiality
high
high

Platform commercialization delay

Launch timing depends on technical validation, customer adoption, and operational readiness.

Scope
Nautilus Voyager platform
Materiality
high
high

Competitive pressure

Established tools companies and emerging proteomics firms may outpace Nautilus in productization and sales.

Scope
Proteomics market
Materiality
high
medium

Third-party manufacturing dependence

Key components are sourced externally and assembly may rely on partners, creating supply and quality risk.

Scope
Instrumentation supply chain
Materiality
medium
medium

Customer funding sensitivity

Demand depends on research spending by pharma, biotech, and academic institutions.

Scope
End-market demand
Materiality
medium
Research and development expense
Affects operating loss and cash burn
Stock-based compensation
Affects operating expenses and dilution analysis
Future revenue recognition
Could affect quarterly comparability and gross margin presentation
Inventory and manufacturing estimates
Could affect cost of revenue and working capital

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

Moleculin Biotech, Inc.

MBRX · Pharmaceutical Preparations

Nauticus Robotics, Inc.

KITT · General Industrial Machinery & Equipment, NEC

ANAPTYSBIO, INC

ANAB · Pharmaceutical Preparations

CITIUS ONCOLOGY, INC.

CTOR · Pharmaceutical Preparations

Matinas BioPharma Holdings, Inc.

MTNB · Pharmaceutical Preparations

: 29.4.2026